The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: A matched cohort study

International Journal of Infectious Diseases

Volumn 36, Issue , 2015, Pages e31-e38

  Asensio, Angel ^a,b   Di Bella, Stefano ^c   Lo Vecchio, Andrea ^d   Grau, Santiago ^e   Hart, Warren M ^f   Isidoro, Beatriz ^g   Scotto, Ricardo ^d   Petrosillo, Nicola ^c   Watt, Maureen ^h   Nazir, Jameel ^h  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f EcoStat Consulting UK   (United Kingdom)

^g Grupo HM Hospitales   (Spain)

^h Astellas Pharma Europe Ltd   (United Kingdom)

Author keywords

CDI; Clostridium difficile infection; Cost burden; Hospital length of stay; Matched cohort analysis

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ATTRIBUTABLE RISK; CHILD; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME VARIABLE; PEPTOCLOSTRIDIUM DIFFICILE; SPAIN; CLOSTRIDIUM INFECTIONS; ECONOMICS; HEALTH CARE PLANNING; HOSPITAL COST; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; FEMALE; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; ITALY; LENGTH OF STAY; MALE; MIDDLE AGED; SPAIN; YOUNG ADULT;

EID: 84930940050     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.05.013     Document Type: Article

References (39)

1. Khanna S., Pardi D.S. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Exp Rev Gastroenterol Hepatol 2010, 4:409-416.
2. Lo Vecchio A., Zacur G.M. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012, 28:1-9.
3. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
4. Khanna S., Pardi D.S. Clostridium difficile infection: new insights into management. Mayo Clin Proc 2012, 87:1106-1117.
5. Morillo S.G., Timenetsky Mdo C. Norovirus: an overview. Rev Assoc Med Bras (1992) 2011, 57:453-458.
6. Tschudin-Sutter S., Tamma P.D., Naegeli A.N., Speck K.A., Milstone A.M., Perl T.M. Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. Clin Infect Dis 2013, 57:1665-1672.
7. Burckhardt F., Friedrich A., Beier D., Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 2008, 14:691-692.
8. Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Orenstein R., St Sauver J.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107:89-95.
9. Pepin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
10. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
11. Barbut F., Delmee M., Brazier J.S., Petit J.C., Poxton I.R., Rupnik M., et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003, 9:989-996.
12. Freeman J., Bauer M.P., Baines S.D., Corver J., Fawley W.N., Goorhuis B., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
13. Longtin Y., Trottier S., Brochu G., Paquet-Bolduc B., Garenc C., Loungnarath V., et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013, 56:67-73.
14. Asensio A., Vaque-Rafart J., Calbo-Torrecillas F., Gestal-Otero J.J., Lopez-Fernandez F., Trilla-Garcia A., et al. Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007. Euro Surveill 2008, 13(31). pii=18943.
15. Alcala L., Marin M., Martin A., Sanchez-Somolinos M., Catalan P., Pelaez M.T., et al. Laboratory diagnosis of Clostridium difficile infection in Spain: a population-based survey. J Hosp Infect 2011, 79:13-17.
16. Rodriguez-Pardo D., Almirante B., Bartolome R.M., Pomar V., Mirelis B., Navarro F., et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol 2013, 51:1465-1473.
17. Di Bella S., Musso M., Cataldo M.A., Meledandri M., Bordi E., Capozzi D., et al. Clostridium difficile infection in Italian urban hospitals. Data from 2006 through 2011. BMC Infect Dis 2013, 13:146.
18. Monge D., Millan I., Gonzalez-Escalada A., Asensio A. [The effect of Clostridium difficile infection on length of hospital stay. A cohort study]. Enferm Infecc Microbiol Clin 2013, 31:660-664.
19. Magalini S., Pepe G., Panunzi S., Spada P.L., De Gaetano A., Gui D. An economic evaluation of Clostridium difficile infection management in an Italian hospital environment. Eur Rev Med Pharmacol Sci 2012, 16:2136-2141.
20. Sammons J.S., Localio R., Xiao R., Coffin S.E., Zaoutis T. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013, 57:1-8.
21. Song X., Bartlett J.G., Speck K., Naegeli A., Carroll K., Perl T.M. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008, 29:823-828.
22. Wiegand P.N., Nathwani D., Wilcox M.H., Stephens J., Shelbaya A., Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012, 81:1-14.
23. Knaus W.A., Wagner D.P., Draper E.A., Zimmerman J.E., Bergner M., Bastos P.G., et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100:1619-1636.
24. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
25. McCabe W.R., Jackson G.G. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 1962, 110:847-855.
26. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
27. Asensio A., Bouza E., Grau S., Rubio-Rodriguez D., Rubio-Terres C. [Cost of Clostridium difficile associated diarrhea in Spain]. Rev Esp Salud Publica 2013, 87:25-33.
28. Consumer prices: data and information 2014, National Institute of Statistics, Istat, Rome, Italy.
29. Dubberke E.R., Butler A.M., Reske K.A., Agniel D., Olsen M.A., D'Angelo G., et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008, 14:1031-1038.
30. Tabak Y.P., Zilberberg M.D., Johannes R.S., Sun X., McDonald L.C. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol 2013, 34:588-596.
31. Eckmann C., Wasserman M., Latif F., Roberts G., Beriot-Mathiot A. Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. Eur J Health Econ 2013, 14:835-846.
32. Pop-Vicas A., Shaban E., Letourneau C., Pechie A. Empirical antimicrobial prescriptions in patients with Clostridium difficile infection at hospital admission and impact on clinical outcome. Infect Control Hosp Epidemiol 2012, 33:1101-1106.
33. Schutze G.E., Willoughby R.E. Clostridium difficile infection in infants and children. Pediatrics 2013, 131:196-200.
34. Lessa F.C., Gould C.V., McDonald L.C. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012, 55(Suppl 2):S65-S70.
35. Forster A.J., Taljaard M., Oake N., Wilson K., Roth V., van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ 2012, 184:37-42.
36. Jones A.M., Kuijper E.J., Wilcox M.H. Clostridium difficile: a European perspective. J Infect 2013, 66:115-128.
37. Cornely O.A. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?. Clin Microbiol Infect 2012, 18(Suppl 6):28-35.
38. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
39. Cornely O.A., Nathwani D., Ivanescu C., Odufowora-Sita O., Retsa P., Odeyemi I.A. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014, 69:2892-2900.